OTTMUSG00000019256 Inhibitors
Inhibiting LOC625713 isoform X1 involves targeting key pathways and molecular mechanisms that regulate its activity. The majority of the selected inhibitors act on the phosphoinositide 3-kinases (PI3K)/AKT/mTOR pathway, which is integral to the function of LOC625713 isoform X1. Rapamycin, for example, forms a complex with FKBP12 that inhibits mTOR, a central kinase in this pathway. This inhibition disrupts downstream signaling involving LOC625713 isoform X1, leading to its functional reduction. Similarly, everolimus and Torin 1 also target mTOR, but with varying mechanisms and specificities. Everolimus forms a complex with FKBP12 to inhibit mTOR, while Torin 1 is a selective inhibitor of both mTORC1 and mTORC2 complexes, leading to a decrease in LOC625713 isoform X1 activity.
Other inhibitors like Wortmannin and LY294002 specifically target PI3Ks, leading to a suppression of the entire PI3K/AKT/mTOR pathway. This suppression is crucial as it leads to the decreased activity of LOC625713 isoform X1. Triciribine, which targets AKT, and PP242, an ATP-competitive inhibitor of mTOR, also follow this inhibition strategy. Ku-0063794, PI-103, AZD8055, Palomid 529, and ZSTK474 further exemplify this approach. Ku-0063794 and AZD8055 are selective inhibitors of mTORC1 and mTORC2, whereas PI-103 and Palomid 529 are dual inhibitors of PI3K and mTOR. ZSTK474's inhibition of PI3K leads to reduced activity of downstream targets, including LOC625713 isoform X1. These inhibitors, through their specific actions on different components of the PI3K/AKT/mTOR pathway, effectively reduce the functional activity of LOC625713 isoform X1, highlighting the pivotal role of this signaling pathway in regulating the protein's activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12, forming a complex that inhibits mTOR, a key kinase in cellular growth and metabolism. The inhibition of mTOR disrupts downstream signaling pathways, including those involving LOC625713 isoform X1, leading to a reduction in its functional activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks). By inhibiting PI3K, wortmannin suppresses the PI3K/AKT/mTOR pathway. This suppression leads to decreased activity of downstream effectors, including LOC625713 isoform X1, hence inhibiting its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of PI3Ks. By blocking PI3K activity, LY294002 disrupts the PI3K/AKT signaling pathway. This disruption results in the downregulation of mTOR activity, which is crucial for the functioning of LOC625713 isoform X1, thereby inhibiting its activity. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $102.00 $138.00 | 14 | |
Triciribine specifically targets AKT, a key component in the PI3K/AKT/mTOR pathway. By inhibiting AKT, triciribine indirectly reduces the activity of mTOR, a kinase that is essential for LOC625713 isoform X1 activity, leading to its functional inhibition. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
Everolimus is an mTOR inhibitor. It binds to FKBP12, and the resultant complex inhibits mTOR activity. Inhibition of mTOR leads to reduced activity of downstream signaling pathways, which are critical for the function of LOC625713 isoform X1, effectively inhibiting its activity. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $240.00 | 7 | |
Torin 1 is a selective inhibitor of mTORC1 and mTORC2. It directly inhibits mTOR kinase activity, leading to decreased signaling through pathways that involve LOC625713 isoform X1, thus inhibiting its functional activity. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
PP242 is an ATP-competitive inhibitor of mTOR. By inhibiting mTOR, PP242 disrupts the mTOR signaling pathway, which plays a crucial role in the regulation of LOC625713 isoform X1, thereby inhibiting its functional activity. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
Ku-0063794 is a selective inhibitor of both mTORC1 and mTORC2. Its inhibition of mTOR kinase activity leads to a decrease in the downstream signaling that is essential for the activity of LOC625713 isoform X1, resulting in its functional inhibition. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI-103 is a dual inhibitor of PI3K and mTOR. By inhibiting both kinases, PI-103 disrupts the PI3K/AKT/mTOR pathway, a key pathway for the functional activity of LOC625713 isoform X1, leading to its inhibition. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $160.00 $345.00 | 12 | |
AZD8055 is an ATP-competitive inhibitor of both mTORC1 and mTORC2. By inhibiting these complexes, AZD8055 disrupts signaling pathways essential for LOC625713 isoform X1, leading to its functional inhibition. | ||||||